DRAFT guidance issued by NICE recommends trifluridine-tiparicil within its marketing authorisation as an option for treating metastatic colorectal cancer in adults who have had previous treatment with available therapies, or when these therapies are not suitable, only when the company provides it with the discount agreed in the patient access scheme.